JP2015511226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511226A5 JP2015511226A5 JP2014554975A JP2014554975A JP2015511226A5 JP 2015511226 A5 JP2015511226 A5 JP 2015511226A5 JP 2014554975 A JP2014554975 A JP 2014554975A JP 2014554975 A JP2014554975 A JP 2014554975A JP 2015511226 A5 JP2015511226 A5 JP 2015511226A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sample
- level
- patient
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593249P | 2012-01-31 | 2012-01-31 | |
| US61/593,249 | 2012-01-31 | ||
| PCT/US2013/023921 WO2013116385A1 (en) | 2012-01-31 | 2013-01-30 | Predictive biomarker for hypoxia-activated prodrug therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214327A Division JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015511226A JP2015511226A (ja) | 2015-04-16 |
| JP2015511226A5 true JP2015511226A5 (enExample) | 2016-03-17 |
Family
ID=48905801
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554975A Pending JP2015511226A (ja) | 2012-01-31 | 2013-01-30 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
| JP2017214327A Withdrawn JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214327A Withdrawn JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150005264A1 (enExample) |
| EP (1) | EP2810076A4 (enExample) |
| JP (2) | JP2015511226A (enExample) |
| WO (1) | WO2013116385A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200800314B (en) | 2005-06-29 | 2009-09-30 | Threshold Pharmaceuticals Inc | Phosphoramidate alkylator prodrugs |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| WO2015025283A2 (en) * | 2013-08-20 | 2015-02-26 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Dual action carbonic anhydrase inhibitors |
| US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| WO2016081547A1 (en) * | 2014-11-19 | 2016-05-26 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| US20210369746A1 (en) * | 2016-08-01 | 2021-12-02 | Molecular Templates, Inc. | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer |
| JP7762796B2 (ja) | 2021-08-27 | 2025-10-30 | アセンタウィッツ ファーマシューティカルズ リミテッド | Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療 |
| WO2023025291A1 (zh) | 2021-08-27 | 2023-03-02 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| EP4509127A4 (en) | 2022-04-15 | 2026-07-15 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR |
| EP4529926A4 (en) | 2022-05-23 | 2026-07-01 | Ascentawits Pharmaceuticals Ltd | CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
| EP4674418A1 (en) | 2023-02-27 | 2026-01-07 | Ascentawits Pharmaceuticals, Ltd. | Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method |
| EP4755396A1 (en) | 2023-07-28 | 2026-06-10 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
| CN121985960A (zh) | 2023-10-18 | 2026-05-05 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003217606C1 (en) * | 2002-02-21 | 2008-07-17 | Institute Of Virology | Soluble Form of Carbonic Anhydrase IX (s-CA IX), Assays to Detect s-CA IX, CA IXs Coexpression with HER-2/neu/c-erbB-2 and CA IX-Specific Monoclonal Antibodies to Non-Immunodominant Epitopes |
| AU2005241093B2 (en) * | 2004-05-04 | 2008-06-05 | Institute Of Virology Of Slovak Academy Of Sciences | MN/CA IX/ CA9 and renal cancer prognosis |
| RU2597844C2 (ru) * | 2010-07-12 | 2016-09-20 | Тресхолд Фармасьютикалз, Инк. | Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака |
-
2013
- 2013-01-30 WO PCT/US2013/023921 patent/WO2013116385A1/en not_active Ceased
- 2013-01-30 US US14/375,417 patent/US20150005264A1/en not_active Abandoned
- 2013-01-30 EP EP13744373.5A patent/EP2810076A4/en not_active Withdrawn
- 2013-01-30 JP JP2014554975A patent/JP2015511226A/ja active Pending
-
2017
- 2017-11-07 JP JP2017214327A patent/JP2018052956A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saad et al. | ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer | |
| Paez‐Ribes et al. | Targeting senescent cells in translational medicine | |
| Wu et al. | IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms | |
| Wu et al. | Heat shock proteins and cancer | |
| Thomas et al. | Advancing therapeutics in small-cell lung cancer | |
| Singh et al. | Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma | |
| JP2016513640A5 (enExample) | ||
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| JP2018503618A5 (enExample) | ||
| BR112015026095A8 (pt) | método de utilizar biomarcadores responsivos ao tumor, método para seleção de pelo menos uma droga antitumoral, composição compreendendo uma droga antitumoral, combinação para controlar a dosagem de uma droga antitumoral, uso dos biomarcadores responsivos ao tumor | |
| EA201290712A1 (ru) | Альфа-излучающие комплексы | |
| Zhu et al. | REGγ drives Lgr5+ stem cells to potentiate radiation induced intestinal regeneration | |
| JP2016535009A5 (enExample) | ||
| TR201909355T4 (tr) | Oral uygulama için proton bağlayıcı polimerler. | |
| Jeong et al. | Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors | |
| DOP2011000282A (es) | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| JP2019537619A5 (enExample) | ||
| Miller et al. | Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis | |
| JP2015508903A5 (enExample) | ||
| Cañadas et al. | Angiopoietin-2 is a negative prognostic marker in small cell lung cancer | |
| Martin-Liberal et al. | Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours | |
| JP2018537519A5 (enExample) | ||
| Greening et al. | Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways | |
| RU2016135933A (ru) | Композиция для противоракового вспомогательного лекарственного средства, содержащая средство, индуцирующее экспрессию rip3, в качестве активного ингредиента, способ скрининга противоракового вспомогательного лекарственного средства, повышающего чувствительность к противораковому лекарственному средству путем стимуляции экспрессии rip3, и способ контроля чувствительности к противораковому лекарственному средству |